Mr. Chris Rivera of EMulate Therapeutics reports

EMULATE THERAPEUTICS FORMS TECHNOLOGY ADVISORY COMMITTEE TO PROMOTE GROWTH AND INNOVATION

Hapbee Technologies Inc. licensor EMulate Therapeutics Inc. has formed a new technology advisory committee that will bring expertise across multiple disciplines to facilitate company growth and innovation.

EMulate Therapeutics' platform technology has broad applications across several therapeutic areas. The creation of this technology advisory committee will serve as an advisory resource to facilitate a process for strategic thinking, technology planning and decision-making to advance the development and adoption of medical, health and environmental applications of ulRFE technology moving forward.

The committee's seven board positions will include:

• Victor Levin, MD, professor emeritus of neuro-oncology at the University of Texas M.D. Anderson Cancer Center;
• Michael Prados, MD, neuro-oncologist and professor emeritus, department of neurological surgery and department of pediatrics, University of California, San Francisco;
• Brian Mogen, PhD, expert in translational science and neuromodulation and next-generation electronics and software platforms in both the medical and non-medical spaces;
• Michael Mischke-Reeds, co-founder and former managing partner of Keelin Reeds Partners, a biotech management consulting firm providing valuation, strategy, portfolio and transaction support services;
• Xavier Figueroa, PhD, principal scientist for EMulate Therapeutics;
• Chris Rivera, president, chief executive officer and chairman of EMulate Therapeutics;
• Bennett (Mike) Butters, the founder and principal inventor of EMulate Therapeutics technology.

"We are extremely pleased to announce the formation of EMulate Therapeutics' multidisciplinary technology advisory committee, representing a significant step forward in product development and furtherance of our long-term business strategy for EMulate Therapeutics and its subsidiaries," said Mr. Rivera, president and chief executive officer of EMulate Therapeutics. "This committee will add unique perspectives across several of our business verticals that will be critical as we advance these programs to the next stage of development."

We seek Safe Harbor.